Breaking News Instant updates and real-time market news.

MNLO

Menlo Therapeutics

$35.22

-1 (-2.76%)

10:27
04/09/18
04/09
10:27
04/09/18
10:27

Menlo Therapeutics sinks after Phase 2 trial of serlopitant misses endpoints

Shares of Menlo Therapeutics are falling after the company announced its Phase 2 clinical trial of serlopitant did not meet its primary or key secondary endpoints. MTI-103 RESULTS: On Sunday, Menlo Therapeutics, which went public on January 25, announced results from MTI-103, the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis. The study did not meet its primary or key secondary efficacy endpoints, and the trial showed no statistically significant difference between patients treated with serlopitant and patients treated with placebo. The ATOMIK, MTI-103 study, was a multi-center, randomized, placebo-controlled Phase 2 clinical trial conducted at 52 U.S. sites to assess the efficacy, safety and tolerability of serlopitant. The primary efficacy analysis compared the difference between serlopitant and placebo in the mean change in worst-itch numeric rating scale from baseline to week 6. A key secondary endpoint was a responder-rate analysis of a 4-point WI-NRS improvement at week 6. EXECUTIVE COMMENTARY: "While we are disappointed that the results in this Phase 2 trial of pruritus associated with atopic dermatitis did not reach statistical significance and did not show the same magnitude of treatment effect as in our prior pruritus studies, we do see in the results a pattern that shows numerical improvement in each serlopitant treatment group above the placebo group at every timepoint. This is our third pruritus study of serlopitant. Reduction of pruritus has been demonstrated in two prior Phase 2 studies, one trial in patients with chronic pruritus and one trial in patients with prurigo nodularis," said Chief Executive Officer Steve Basta. "We are initiating Phase 3 studies in prurigo nodularis this quarter, and we are looking forward to the Phase 2 results in refractory chronic cough in the fourth quarter of this year, and the Phase 2 results in pruritus associated with psoriasis by late 2018 or early 2019." ANALYST REACTION: On Monday, Jefferies analyst David Steinberg downgraded Menlo Therapeutics to Hold and cut his price target for shares to $20 from $41. The analyst said he is surprised that the Phase 2 clinical trial of serlopitant did not meet its primary or key secondary efficacy endpoints and has removed all revenue linked with the atopic dermatitis indication from his model. Steinberg continues to project successful outcomes for serlopitant's other ongoing development programs and looks forward to the key clinical data readouts in coming months, including Ph2 chronic cough data in the fourth quarter and Phase 2 pruritus associated with psoriasis data in late 2018/early 2019. Meanwhile, Piper Jaffray analyst David Amsellem called the miss of primary and secondary endpoints in the Phase IIb study a "big disappointment." The analyst, however, does not infer that the setback in atopic dermatitis "necessarily raises the risk" surrounding the prurigo nodularis Phase III trials. Prurigo nodularis is an altogether different condition, Amsellem told investors. He believes the trial miss "should not call into question the overall viability of serlopitant as an anti-pruritic agent." Amsellem reiterated an Overweight rating and $48 price target on Menlo Therapeutics. PRICE ACTION: Shares of Menlo Therapeutics have lost more than half their value on Monday morning, declining 71.3% to $10.09 in morning trading.

MNLO Menlo Therapeutics
$35.22

-1 (-2.76%)

02/20/18
JMPS
02/20/18
INITIATION
Target $44
JMPS
Outperform
Menlo Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started Menlo Therapeutics with an Outperform rating and $44 price target, nothing that he forecasts launches of treatments of prurigo nodularis, psoriasis and atopic dermatitis in early 2022. Ellis believes the U.S. pruritus market could easily exceed $1B, he tells investors.
02/20/18
02/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Imax (IMAX) assumed with an Overweight at JPMorgan. 2. Gates Industrial (GTES) was initiated with an Outperform at RBC Capital and Credit Suisse, an Overweight at Morgan Stanley and KeyBanc, as well as a Buy at SunTrust, UBS, and Citi. 3. Menlo Therapeutics (MNLO) was initiated with an Outperform at JMP Securities, an Overweight at Piper Jaffray, and a Buy at Jefferies. 4. PlayAGS (AGS) was initiated with a Buy at SunTrust, BofA/Merrill, and Deutsche Bank. 5. PagSeguro Digital (PAGS) was initiated with a Neutral at JPMorgan, BofA/Merrill, UBS, and Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $20
JEFF
Hold
Menlo Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies analyst David Steinberg downgraded Menlo Therapeutics to Hold and cut his price target for the shares to $20 from $41. The analyst is surprised that the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis did not meet its primary or key secondary efficacy endpoints.
04/09/18
PIPR
04/09/18
NO CHANGE
Target $48
PIPR
Overweight
Piper reiterates Overweight on Menlo Therapeutics after Phase II miss
Piper Jaffray analyst David Amsellem calls Menlo Therapeutics' serlopitant missing the primary and secondary endpoints in a Phase IIb study in patients with pruritis associated with atopic dermatitis as "big disappointment." The analyst, however, does not infer that the setback in atopic dermatitis "necessarily raises the risk" surrounding the prurigo nodularis Phase III trials. Prurigo nodularis is an altogether different condition, Amsellem tells investors in a research note. He believes last night's trial miss "should not call into question the overall viability of serlopitant as an anti-pruritic agent." Amsellem reiterates an Overweight rating on Menlo Therapeutics.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

, TWX

Time Warner

$96.23

-0.34 (-0.35%)

08:34
04/21/18
04/21
08:34
04/21/18
08:34
Periodicals
Trump's tweets politicize U.S. markets, Barron's says »

With President Donald…

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

TWX

Time Warner

$96.23

-0.34 (-0.35%)

T

AT&T

$34.67

-0.15 (-0.43%)

MYL

Mylan

$40.73

-0.08 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 18

    May

  • 13

    Nov

FB

Facebook

$166.29

-1.82 (-1.08%)

, AAPL

Apple

$165.71

-7.08 (-4.10%)

08:15
04/21/18
04/21
08:15
04/21/18
08:15
Periodicals
Facebook, Apple embody new tech divide, Barron's says »

For several years now,…

FB

Facebook

$166.29

-1.82 (-1.08%)

AAPL

Apple

$165.71

-7.08 (-4.10%)

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

NFLX

Netflix

$327.57

-5.12 (-1.54%)

GOOG

Alphabet

$1,072.73

-15.18 (-1.40%)

GOOGL

Alphabet Class A

$1,076.64

-12.83 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 25

    Apr

  • 26

    Apr

  • 01

    May

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

, ACIA

Acacia Communications

$27.54

1.04 (3.92%)

08:00
04/21/18
04/21
08:00
04/21/18
08:00
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

ACIA

Acacia Communications

$27.54

1.04 (3.92%)

OCLR

Oclaro

$8.27

0.08 (0.98%)

NOK

Nokia

$5.96

0.125 (2.14%)

NPTN

NeoPhotonics

$6.05

-0.01 (-0.17%)

LITE

Lumentum

$58.90

-1.05 (-1.75%)

FNSR

Finisar

$15.43

0.045 (0.29%)

MSFT

Microsoft

$95.01

-1.1 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 09

    May

  • 23

    May

  • 29

    May

  • 12

    Jun

  • 26

    Jun

04:55
04/21/18
04/21
04:55
04/21/18
04:55
Conference/Events
International Monetary Fund & World Bank Group to co-host an annual meeting »

2018 Spring Meeting will…

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.66

-2.18 (-0.81%)

18:08
04/20/18
04/20
18:08
04/20/18
18:08
Periodicals
North Korea to suspend nuclear and ICBM tests, Bloomberg reports »

North Korea also plans to…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.66

-2.18 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADM

Archer Daniels

$45.50

-0.295 (-0.64%)

, BG

Bunge

$73.72

-1.935 (-2.56%)

18:03
04/20/18
04/20
18:03
04/20/18
18:03
Periodicals
Archer Daniels, Bunge talks end without merger deal, Bloomberg reports »

Advanced merger…

ADM

Archer Daniels

$45.50

-0.295 (-0.64%)

BG

Bunge

$73.72

-1.935 (-2.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 30

    May

CE

Celanese

$111.69

0.56 (0.50%)

18:02
04/20/18
04/20
18:02
04/20/18
18:02
Hot Stocks
Celanese announces price increases in Asia »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

IOTS

Adesto Technologies

$8.65

-0.2 (-2.26%)

17:33
04/20/18
04/20
17:33
04/20/18
17:33
Hot Stocks
Breaking Hot Stocks news story on Adesto Technologies »

180 Degree Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SIGM

Sigma Designs

$6.30

0.1 (1.61%)

17:22
04/20/18
04/20
17:22
04/20/18
17:22
Hot Stocks
Sigma Designs to delay filing Annual Report on Form 10-K »

Sigma Designs is unable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$300,140.00

-260 (-0.09%)

, BRK.B

Berkshire Hathaway

$200.09

-0.32 (-0.16%)

17:22
04/20/18
04/20
17:22
04/20/18
17:22
Hot Stocks
Breaking Hot Stocks news story on Berkshire Hathaway, Berkshire Hathaway, Torchmark »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$300,140.00

-260 (-0.09%)

BRK.B

Berkshire Hathaway

$200.09

-0.32 (-0.16%)

TMK

Torchmark

$87.22

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMHI

SEACOR Marine Holdings

$22.90

-0.86 (-3.62%)

, CG

Carlyle Group

$20.85

0.15 (0.72%)

17:17
04/20/18
04/20
17:17
04/20/18
17:17
Syndicate
SEACOR Marine Holdings announces $56.9M private placement of common stock »

SEACOR Marine Holdings…

SMHI

SEACOR Marine Holdings

$22.90

-0.86 (-3.62%)

CG

Carlyle Group

$20.85

0.15 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

AVAV

AeroVironment

$56.66

-0.15 (-0.26%)

17:12
04/20/18
04/20
17:12
04/20/18
17:12
Hot Stocks
AeroVironment awarded $44.7M U.S. Army contract modification »

AeroVironment was awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

XLE

Energy Select Sector SPDR

$73.30

-0.36 (-0.49%)

, XLU

Utilities SPDR

$50.29

-0.45 (-0.89%)

17:10
04/20/18
04/20
17:10
04/20/18
17:10
General news
Week ending ETF Scorecard: Energy outperforms again, Staples lag »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$73.30

-0.36 (-0.49%)

XLU

Utilities SPDR

$50.29

-0.45 (-0.89%)

IYR

DJ US Real Estate Index Fund

$73.94

-0.62 (-0.83%)

XLP

Consumer Staples Sector SPDR

$50.49

-0.85 (-1.66%)

XLY

Consumer Discretionary Sector SPDR

$102.97

-1.06 (-1.02%)

XLB

S&P Select Materials SPDR

$59.00

-0.36 (-0.61%)

XLF

Financial Select Sector

$27.89

0.015 (0.05%)

XLV

Health Care Select Sector SPDR

$82.10

-0.45 (-0.55%)

XLK

Technology Select Sector SPDR

$66.18

-0.97 (-1.44%)

XLI

Industrial Select Sector SPDR

$75.59

-0.32 (-0.42%)

GLD

SPDR Gold Trust

$126.61

-1.01 (-0.79%)

SLV

iShares Silver Trust

$16.14

-0.11 (-0.68%)

USO

United States Oil Fund

$13.76

-0.01 (-0.07%)

UNG

United States Natural Gas Fund

$22.56

0.475 (2.15%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.91

-0.19 (-0.22%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.47

-0.49 (-0.42%)

TLT

iShares 20+ Year Treasury Bond Fund

$118.47

-0.88 (-0.74%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.57

-0.355 (-0.35%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.03 (-0.04%)

IWD

iShares Russell 1000 Value

$121.38

-0.61 (-0.50%)

IWF

iShares Russell 1000 Growth

$137.65

-1.53 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.16

-0.0051 (-3.02%)

17:07
04/20/18
04/20
17:07
04/20/18
17:07
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$86.98

-0.9 (-1.02%)

, FB

Facebook

$166.29

-1.82 (-1.08%)

17:05
04/20/18
04/20
17:05
04/20/18
17:05
Hot Stocks
Walmart says Kevin Systrom will not stand for re-election to board »

Walmart and Systrom, the…

WMT

Walmart

$86.98

-0.9 (-1.02%)

FB

Facebook

$166.29

-1.82 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

  • 17

    May

  • 30

    May

  • 01

    Jun

WMT

Walmart

$86.98

-0.9 (-1.02%)

, MCD

McDonald's

$158.77

-0.76 (-0.48%)

17:03
04/20/18
04/20
17:03
04/20/18
17:03
Hot Stocks
Walmart announces McDonald's Steve Easterbrook as independent nominee to board »

"This year's…

WMT

Walmart

$86.98

-0.9 (-1.02%)

MCD

McDonald's

$158.77

-0.76 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 30

    Apr

  • 17

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 01

    Jun

SPY

SPDR S&P 500 ETF Trust

$266.66

-2.18 (-0.81%)

, USO

United States Oil Fund

$13.76

-0.01 (-0.07%)

17:00
04/20/18
04/20
17:00
04/20/18
17:00
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.5K…

SPY

SPDR S&P 500 ETF Trust

$266.66

-2.18 (-0.81%)

USO

United States Oil Fund

$13.76

-0.01 (-0.07%)

GLD

SPDR Gold Trust

$126.61

-1.01 (-0.79%)

FXE

Euro Currency Trust

$118.04

-0.65 (-0.55%)

FXC

CurrencyShares Canadian Dollar Trust

$77.37

-0.54 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXR

Citius Pharmaceuticals

$2.86

0.01 (0.35%)

16:59
04/20/18
04/20
16:59
04/20/18
16:59
Syndicate
Breaking Syndicate news story on Citius Pharmaceuticals »

Citius Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
04/20/18
04/20
16:55
04/20/18
16:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

FPI

Farmland Partners

$7.85

-0.24 (-2.97%)

16:51
04/20/18
04/20
16:51
04/20/18
16:51
Syndicate
Breaking Syndicate news story on Farmland Partners »

Farmland Partners files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$8.85

0.05 (0.57%)

16:51
04/20/18
04/20
16:51
04/20/18
16:51
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

PVAM Perlus Microcap Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

AMID

American Midstream Partners

$11.45

-0.1 (-0.87%)

16:46
04/20/18
04/20
16:46
04/20/18
16:46
Syndicate
American Midstream Partners files $150M preferred unit offering »

The offering is for $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMID

American Midstream Partners

$11.45

-0.1 (-0.87%)

16:41
04/20/18
04/20
16:41
04/20/18
16:41
Syndicate
American Midstream Partners requests withdrawal of registration statement »

The Partnership has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSC

Seven Stars Cloud Group

$2.67

-0.1 (-3.61%)

16:40
04/20/18
04/20
16:40
04/20/18
16:40
Syndicate
Breaking Syndicate news story on Seven Stars Cloud Group »

Seven Stars Cloud Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNI

HNI Corporation

$35.35

-0.28 (-0.79%)

16:39
04/20/18
04/20
16:39
04/20/18
16:39
Hot Stocks
HNI Corporation CEO says 'seeing increased inflationary pressures' »

"We continue to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 24

    May

  • 25

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.